OptiBiotix Health Plc., a leading life sciences company focused on harnessing the power of human microbiome modulation to tackle obesity, high cholesterol and diabetes, will showcase the results of a recent study involving its revolutionary probiotic product LPLDL® at Probiota Americas next month.

The study will be presented during a poster viewing at the show, held in Miami, Florida, June 5-7, 2018. Dr. Luis Gosalbez, Director of Business Development at OptiBiotix, will be on hand to discuss the findings of the study and OptiBiotix’s functional ingredient, LPLDL®, which promotes cardiovascular health.

The poster demonstrates the results of a recent double blind human intervention study, to confirm the product’s efficacy and safety in adults with normal to mildly elevated total cholesterol. The active group took LPLDL® twice daily for 12 weeks and the placebo group received identical capsules without the probiotic.

Participants who took LPLDL® experienced significant results, including LDL-cholesterol reduction, baseline total cholesterol reduction and improved blood pressure. In addition, active treatment in the over 60s group resulted in significant increases of ‘good’ HDL-cholesterol as well as reduced triglycerides.

Dr. Gosalbez said: “The results of this study confirm the safety and efficacy of LPLDL® to impact positively on cholesterol and other cardiovascular risk factors. Probiota Americas attendees will be able to hear first-hand about the exciting, measurable results of this study and the huge potential harnessing the human microbiome for health presents.”

Held at the Marriot Biscayne Bay in Miami, Florida, Probiota Americas is the leading annual event for the prebiotic, probiotic and the microbiota focused food and pharma industries in the Americas. The poster will be exhibited as part of the event’s Networking Reception and Poster Viewing, at 6:30pm on June 5. Dr. Gosalbez will be on hand to discuss the study results and answer any questions about LPLDL®.